Volume 1, Issue 3, December 2008

• Editorial By Vincenzo Di Marzo, PhD George Kunos, MD pages 3-6
• Pathogenesis of the metabolic syndrome and the influence of cannabinoids By Richard N. Bergman, PhD pages 7-9
• Physiological and pathophysiological functions of the endocannabinoid system in the central nervous system By Beat Lutz, PhD pages 10-13
• Peripheral functions of the endocannabinoid system: pathology and physiology By Andreas Zimmer, PhD pages 14-17
• The endocannabinoid system and stress By Cecilia J. Hillard, PhD pages 18-21
• Endocannabinoids and non-homeostatic controls of appetite By Tim C. Kirkham, PhD pages 22-26
• The endocannabinoid system and the control of gastrointestinal function By Keith A. Sharkey, PhD pages 27-30
• The endocannabinoid system in adipose tissue function By Uberto Pagotto, MD, PhD pages 31-35
• The endocannabinoid system as a therapeutic target for liver diseases By Sophie Lotersztajn, PhD Ariane Mallat, MD, PhD pages 36-40
• The endocannabinoid system and cardiovascular disease By Pal Pacher, MD, PhD, FAPS, FAHA pages 41-44
• Role of the endocannabinoid system in atherosclerosis By François Mach, MD Fabrizio Montecucco, MD Sabine Steffens, PhD pages 45-46
• History of the development and clinical use of CB1 receptor inverse agonists/antagonists By Gérard Le Fur, PhD pages 47-50
• Abdominal obesity, dyslipidemia, insulin resistance, type 2 diabetes and atherosclerosis: who is the right patient to be treated with CB1 receptor antagonists? By Luc F. Van Gaal, MD, PhD
  Jean-Pierre Després, PhD, FAHA pages 51-56